{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/sop-for-ictrp-trial-registration-alignment-who-registry-expectations”
},
“headline”: “SOP for ICTRP Trial Registration Alignment (WHO Registry Expectations)”,
“description”: “This SOP defines procedures for aligning clinical trial registration with the WHO International Clinical Trials Registry Platform (ICTRP). It establishes responsibilities for sponsors, CROs, and investigators to ensure transparency, compliance, and public accessibility of trial data.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Standard Operating Procedure for ICTRP Trial Registration Alignment (WHO Registry Expectations)

Purpose

The purpose of this SOP is to outline procedures for aligning clinical trial registration with the World Health Organization’s International Clinical Trials Registry Platform (ICTRP). It ensures transparency, ethical compliance, and accessibility of trial data to the global scientific community and public health stakeholders.

Scope

This SOP applies to sponsors, CROs, investigators, and regulatory affairs teams responsible for clinical trial registration. It covers registration with WHO ICTRP-recognized primary registries, updates, result postings, and inspection readiness for compliance with WHO and ICMJE requirements.

Responsibilities

• Sponsor: Ensures timely registration and posting of trial data in ICTRP-recognized registries.
• CRO: Coordinates registration process and maintains compliance on behalf of the sponsor.
• Investigator: Provides accurate trial information for registry submissions.
• Regulatory Affairs: Tracks registration timelines and compliance with country-specific registries.
• QA: Audits registry submissions for accuracy and completeness.

Accountability

The Sponsor is accountable for ensuring alignment with WHO ICTRP trial registration and result posting requirements, even when delegated to CROs.

Procedure

1. Trial Identification
1.1 Identify registry platform recognized by WHO ICTRP (e.g., ClinicalTrials.gov, EU CTR, CTRI).
1.2 Record details in Registry Selection Log (Annexure-1).

2. Initial Registration
2.1 Register trial before enrollment of the first subject.
2.2 Include WHO Trial Registration Data Set (TRDS) elements.
2.3 Document in Registration Log (Annexure-2).

3. Updates and Amendments
3.1 Submit updates within 30 days of protocol amendments.
3.2 Document updates in Amendment Registration Log (Annexure-3).

4. Result Posting
4.1 Post trial results within 12 months of trial completion.
4.2 Archive results in TMF.
4.3 Record in Result Posting Log (Annexure-4).

5. Inspection Readiness
5.1 Ensure registry entries are accurate and up-to-date.
5.2 Maintain inspection-ready records in Registry Audit Log (Annexure-5).

Abbreviations

• SOP: Standard Operating Procedure
• WHO: World Health Organization
• ICTRP: International Clinical Trials Registry Platform
• ICMJE: International Committee of Medical Journal Editors
• TRDS: Trial Registration Data Set
• CRO: Contract Research Organization
• QA: Quality Assurance
• TMF: Trial Master File

Documents

1. Registry Selection Log (Annexure-1)
2. Registration Log (Annexure-2)
3. Amendment Registration Log (Annexure-3)
4. Result Posting Log (Annexure-4)
5. Registry Audit Log (Annexure-5)

References

• WHO ICTRP
• ClinicalTrials.gov
• CTRI – Clinical Trials Registry India

Version: 1.0

Approval Section

Annexures

Annexure-1: Registry Selection Log

Annexure-2: Registration Log

Annexure-3: Amendment Registration Log

Annexure-4: Result Posting Log

Annexure-5: Registry Audit Log

Revision History

For more SOPs visit: Pharma SOP

{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/sop-for-safety-data-exchange-with-global-pv-systems-vigibase-alignment”
},
“headline”: “SOP for Safety Data Exchange with Global PV Systems (VigiBase Alignment)”,
“description”: “This SOP defines procedures for safety data exchange with global pharmacovigilance (PV) systems, including VigiBase. It ensures compliance with WHO expectations, timely adverse event reporting, and harmonization of safety data across international databases.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Standard Operating Procedure for Safety Data Exchange with Global PV Systems (VigiBase Alignment)

Purpose

The purpose of this SOP is to establish standardized procedures for the exchange of safety data with global pharmacovigilance (PV) systems, including VigiBase, the WHO global ICSR (Individual Case Safety Reports) database. This ensures international harmonization, timely reporting, and compliance with WHO pharmacovigilance expectations.

Scope

This SOP applies to sponsors, CROs, pharmacovigilance staff, investigators, and regulatory affairs teams involved in global safety reporting for clinical trials. It covers safety data collection, formatting, validation, exchange with VigiBase, and record-keeping in TMF and safety databases.

Responsibilities

• Sponsor: Ensures timely safety data submissions to global PV systems including VigiBase.
• CRO: Coordinates data exchange and ensures accuracy of submissions.
• PV Department: Prepares and validates ICSRs for electronic submission.
• Investigator: Provides complete and accurate SAE/SUSAR reports.
• QA: Audits safety reporting records for accuracy and compliance.

Accountability

The Sponsor’s Pharmacovigilance Head is accountable for ensuring compliance with WHO safety data exchange requirements and proper alignment with VigiBase.

Procedure

1. Data Collection
1.1 Collect SAE, SUSAR, and other safety data from investigators.
1.2 Verify completeness using ICH E2B(R3) standards.
1.3 Record in Safety Data Collection Log (Annexure-1).

2. Data Validation
2.1 Perform quality checks for completeness and consistency.
2.2 Ensure coding with MedDRA dictionary.
2.3 Record in Safety Data Validation Log (Annexure-2).

3. Data Exchange
3.1 Submit validated ICSRs to VigiBase via national PV center or WHO PV platform.
3.2 Document submission details in Safety Data Exchange Log (Annexure-3).

4. Acknowledgment and Tracking
4.1 Track acknowledgment receipts from VigiBase.
4.2 Document in Safety Acknowledgment Log (Annexure-4).

5. Archiving
5.1 Archive safety submissions and acknowledgments in TMF.
5.2 Document archiving details in Safety Archiving Log (Annexure-5).

Abbreviations

• SOP: Standard Operating Procedure
• PV: Pharmacovigilance
• WHO: World Health Organization
• ICSR: Individual Case Safety Report
• SAE: Serious Adverse Event
• SUSAR: Suspected Unexpected Serious Adverse Reaction
• CRO: Contract Research Organization
• QA: Quality Assurance
• TMF: Trial Master File
• MedDRA: Medical Dictionary for Regulatory Activities

Documents

1. Safety Data Collection Log (Annexure-1)
2. Safety Data Validation Log (Annexure-2)
3. Safety Data Exchange Log (Annexure-3)
4. Safety Acknowledgment Log (Annexure-4)
5. Safety Archiving Log (Annexure-5)

References

• WHO – VigiBase
• ICH GCP Guidelines
• MedDRA – Medical Dictionary for Regulatory Activities

Version: 1.0

Approval Section

Annexures

Annexure-1: Safety Data Collection Log

Annexure-2: Safety Data Validation Log

Annexure-3: Safety Data Exchange Log

Annexure-4: Safety Acknowledgment Log

Annexure-5: Safety Archiving Log

Revision History

For more SOPs visit: Pharma SOP

{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/sop-for-community-engagement-requirements-in-lmic-contexts”
},
“headline”: “SOP for Community Engagement Requirements in LMIC Contexts”,
“description”: “This SOP outlines standardized procedures for community engagement in clinical trials conducted in low- and middle-income countries (LMICs). It ensures compliance with WHO expectations, ethical standards, and cultural sensitivity while fostering trust and transparency with trial communities.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Standard Operating Procedure for Community Engagement Requirements in LMIC Contexts

Purpose

The purpose of this SOP is to define structured community engagement practices for clinical trials conducted in low- and middle-income countries (LMICs). Community engagement ensures ethical trial conduct, cultural sensitivity, trust-building, and alignment with WHO expectations for equitable participation and transparency in clinical research.

Scope

This SOP applies to sponsors, CROs, investigators, community advisory boards (CABs), and ethics committees involved in trials in LMICs. It covers strategies for communication, cultural adaptation, engagement activities, and documentation of community interactions.

Responsibilities

• Sponsor: Ensures trial design includes adequate provisions for community engagement.
• CRO: Coordinates and documents engagement activities at site and community level.
• Investigator: Engages local communities, addresses concerns, and maintains records.
• Community Advisory Boards (CAB): Provides feedback and supports trial acceptability in the local context.
• EC: Reviews engagement strategies as part of ethical approval process.

Accountability

The Principal Investigator (PI) is accountable for ensuring community engagement activities are culturally appropriate, documented, and aligned with WHO ethical guidelines.

Procedure

1. Community Mapping
1.1 Identify relevant community stakeholders (leaders, health workers, NGOs).
1.2 Conduct baseline cultural and literacy assessment.
1.3 Record in Community Mapping Log (Annexure-1).

2. Engagement Planning
2.1 Develop a Community Engagement Plan (CEP) tailored to local context.
2.2 Translate key trial information into local languages.
2.3 Document plan in Engagement Planning Log (Annexure-2).

3. Engagement Activities
3.1 Conduct informational meetings, workshops, and Q&A sessions.
3.2 Establish community advisory boards.
3.3 Document activities in Engagement Activity Log (Annexure-3).

4. Feedback and Grievance Mechanisms
4.1 Implement community feedback systems (meetings, hotlines).
4.2 Record in Feedback and Grievance Log (Annexure-4).

5. Monitoring and Reporting
5.1 Monitor engagement effectiveness using surveys and attendance records.
5.2 Report engagement outcomes to EC and sponsor.
5.3 Document in Monitoring and Reporting Log (Annexure-5).

Abbreviations

• SOP: Standard Operating Procedure
• LMIC: Low- and Middle-Income Countries
• WHO: World Health Organization
• CRO: Contract Research Organization
• EC: Ethics Committee
• PI: Principal Investigator
• CAB: Community Advisory Board

Documents

1. Community Mapping Log (Annexure-1)
2. Engagement Planning Log (Annexure-2)
3. Engagement Activity Log (Annexure-3)
4. Feedback and Grievance Log (Annexure-4)
5. Monitoring and Reporting Log (Annexure-5)

References

• WHO – Clinical Trials Registry Platform
• WHO – Standards and Operational Guidance for Ethics Review of Health-Related Research with Human Participants
• ICMR – National Ethical Guidelines

Version: 1.0

Approval Section

Annexures

Annexure-1: Community Mapping Log

Annexure-2: Engagement Planning Log

Annexure-3: Engagement Activity Log

Annexure-4: Feedback and Grievance Log

Annexure-5: Monitoring and Reporting Log

Revision History

For more SOPs visit: Pharma SOP

{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/sop-for-vaccine-trial-conduct-aligned-with-who-pq-prequalification-guidance”
},
“headline”: “SOP for Vaccine Trial Conduct Aligned with WHO PQ/Prequalification Guidance”,
“description”: “This SOP describes procedures for conducting vaccine trials in alignment with WHO Prequalification (PQ) guidance. It ensures compliance with WHO standards, ethical practices, and readiness for PQ dossier submission supporting global vaccine procurement.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Standard Operating Procedure for Vaccine Trial Conduct Aligned with WHO PQ/Prequalification Guidance

Purpose

The purpose of this SOP is to define standardized procedures for conducting vaccine clinical trials in alignment with World Health Organization (WHO) Prequalification (PQ) guidance. Compliance with PQ ensures that vaccine data supports global procurement and use by United Nations agencies and Gavi, strengthening public health impact.

Scope

This SOP applies to sponsors, CROs, investigators, QA, and regulatory affairs teams engaged in vaccine trials intended for WHO PQ submission. It covers trial design considerations, operational procedures, data integrity requirements, and dossier preparation.

Responsibilities

• Sponsor: Ensures trial design and execution align with WHO PQ guidance and GCP.
• CRO: Oversees operational compliance with PQ trial requirements.
• Investigator: Conducts vaccine trial activities according to protocol, GCP, and PQ standards.
• QA: Audits vaccine trial processes and ensures PQ-readiness of trial data.
• Regulatory Affairs: Coordinates submissions with WHO PQ program.

Accountability

The Sponsor’s Clinical and Regulatory Heads are accountable for ensuring that vaccine trials are PQ-compliant, and trial data is suitable for PQ dossier submission.

Procedure

1. Trial Design and Protocol Development
1.1 Incorporate WHO PQ requirements into vaccine trial protocols.
1.2 Ensure inclusion of appropriate endpoints (safety, immunogenicity, efficacy).
1.3 Document in Protocol Compliance Log (Annexure-1).

2. Site Preparation and Training
2.1 Select PQ-ready trial sites with vaccine cold chain capacity.
2.2 Conduct training for investigators and staff on PQ standards.
2.3 Document in Training Log (Annexure-2).

3. Vaccine Handling and Cold Chain
3.1 Maintain WHO-recommended cold chain conditions (2–8°C unless specified).
3.2 Record in Vaccine Cold Chain Log (Annexure-3).

4. Data Collection and Integrity
4.1 Collect safety, efficacy, and immunogenicity data per PQ requirements.
4.2 Ensure ALCOA+ principles in data capture.
4.3 Document in Data Integrity Log (Annexure-4).

5. SAE and SUSAR Reporting
5.1 Report safety events per WHO PQ requirements.
5.2 Document in Safety Reporting Log (Annexure-5).

6. PQ Dossier Preparation
6.1 Compile PQ dossier sections covering quality, safety, and efficacy.
6.2 Archive dossier documents in TMF.
6.3 Record in PQ Dossier Preparation Log (Annexure-6).

Abbreviations

• SOP: Standard Operating Procedure
• PQ: Prequalification
• WHO: World Health Organization
• CRO: Contract Research Organization
• QA: Quality Assurance
• SAE: Serious Adverse Event
• SUSAR: Suspected Unexpected Serious Adverse Reaction
• TMF: Trial Master File
• GCP: Good Clinical Practice

Documents

1. Protocol Compliance Log (Annexure-1)
2. Training Log (Annexure-2)
3. Vaccine Cold Chain Log (Annexure-3)
4. Data Integrity Log (Annexure-4)
5. Safety Reporting Log (Annexure-5)
6. PQ Dossier Preparation Log (Annexure-6)

References

• WHO Prequalification of Medicines and Vaccines
• ICH GCP Guidelines
• Gavi – The Vaccine Alliance

Version: 1.0

Approval Section

Annexures

Annexure-1: Protocol Compliance Log

Annexure-2: Training Log

Annexure-3: Vaccine Cold Chain Log

Annexure-4: Data Integrity Log

Annexure-5: Safety Reporting Log

Annexure-6: PQ Dossier Preparation Log

Revision History

For more SOPs visit: Pharma SOP

{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/sop-for-data-sharing-transparency-in-public-health-emergencies”
},
“headline”: “SOP for Data Sharing/Transparency in Public Health Emergencies”,
“description”: “This SOP establishes procedures for data sharing and transparency in clinical trials conducted during public health emergencies. It ensures compliance with WHO expectations, ethical imperatives, and rapid dissemination of data for global health protection.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Standard Operating Procedure for Data Sharing/Transparency in Public Health Emergencies

Purpose

The purpose of this SOP is to establish structured procedures for timely data sharing and transparency in clinical trials conducted during public health emergencies (e.g., pandemics, epidemics). It aligns with WHO guidance to ensure that trial results contribute rapidly to public health decision-making, while maintaining ethical and regulatory compliance.

Scope

This SOP applies to sponsors, CROs, investigators, regulatory affairs teams, and data managers involved in trials conducted during emergencies. It covers trial registration, expedited data sharing, publication requirements, and communication with regulators, WHO, and the public.

Responsibilities

• Sponsor: Ensures timely data release to WHO and national authorities.
• CRO: Facilitates operational aspects of emergency data sharing.
• Investigator: Ensures accurate and real-time reporting of trial data.
• Regulatory Affairs: Coordinates communication with health authorities and WHO.
• QA: Audits emergency data sharing records for compliance.

Accountability

The Sponsor’s Regulatory and Clinical Heads are accountable for ensuring that trial data are rapidly and transparently shared with global health authorities during emergencies.

Procedure

1. Trial Registration
1.1 Register trial in WHO ICTRP-recognized registry prior to enrollment.
1.2 Ensure registry updates every 30 days.
1.3 Document in Trial Registration Log (Annexure-1).

2. Interim Data Sharing
2.1 Submit interim safety and efficacy results to WHO and regulators within agreed timelines.
2.2 Share aggregated anonymized data with public health stakeholders.
2.3 Record in Interim Data Sharing Log (Annexure-2).

3. Final Results Disclosure
3.1 Publish trial results within 6 months of study completion in open-access platforms.
3.2 Notify WHO and regulators of data availability.
3.3 Document in Final Results Disclosure Log (Annexure-3).

4. Communication
4.1 Provide regular updates to trial participants and affected communities.
4.2 Maintain transparency through press releases, websites, or public dashboards.
4.3 Document in Communication Log (Annexure-4).

5. Archiving
5.1 Archive shared data, communications, and reports in TMF and ISF.
5.2 Record details in Data Archiving Log (Annexure-5).

Abbreviations

• SOP: Standard Operating Procedure
• WHO: World Health Organization
• ICTRP: International Clinical Trials Registry Platform
• CRO: Contract Research Organization
• QA: Quality Assurance
• TMF: Trial Master File
• ISF: Investigator Site File

Documents

1. Trial Registration Log (Annexure-1)
2. Interim Data Sharing Log (Annexure-2)
3. Final Results Disclosure Log (Annexure-3)
4. Communication Log (Annexure-4)
5. Data Archiving Log (Annexure-5)

References

• WHO – Data Sharing in Public Health Emergencies
• WHO ICTRP
• ICH GCP Guidelines

Version: 1.0

Approval Section

Annexures

Annexure-1: Trial Registration Log

Annexure-2: Interim Data Sharing Log

Annexure-3: Final Results Disclosure Log

Annexure-4: Communication Log

Annexure-5: Data Archiving Log

Revision History

For more SOPs visit: Pharma SOP